Robert F. Kalejta, PhD, will serve as co-leader of the Human Cancer Virology Program. His research focuses on determining the mechanisms of human cytomegalovirus (HCMV) replication and pathogenesis, as well as using the virus as a tool to probe the pathways that lead to cell cycle progression and oncogenesis. Kalejta holds three R01s related to his work with HCMV and is the vice chair of the Institute for Molecular Virology (IMV) and an assistant director of the McArdle Laboratory for Cancer Research. He joins Shannon C. Kenney, MD, as co-leader.
Joshua Lang, MD, was named co-leader of the Tumor Microenvironment Program. His research focuses on biomarker development in prostate cancer for the clinical translation of targeted therapies. This work has extended into translational clinical trials evaluating how the tumor microenvironment promotes treatment resistance in multi-focal prostate cancer. He joins Pam Kreeger, PhD, as co-leader.
Lang, an associate professor of medicine, maintains extensive research partnerships, including working with Dave Beebe, PhD, to co-develop microscale platforms for the analysis of circulating tumor cells (CTCs), serving as co-investigator on the DOD Prostate Cancer Clinical Trials Consortium grant held by Glenn Liu, MD, and holding leadership roles with the UW Carbone Liquid Biospecimen Acquisition Team and Circulating Biomarker Core. Lang is currently funded by an NIH/NCI R01, two Prostate Cancer Foundation grants and multiple DOD/PCRP awards.
Read the full article at: https://www.med.wisc.edu/news-and-events/2019/april/carbone-cancer-center-members-leadership-roles/?fbclid=IwAR1pp5ZMlGUOc4aZmEfcx_ColQXtWSsXAfFOje3mOysUmJ5iw-FKgqdkEus